Bisphosphonates

Skeletal Radiology

Volumn 36, Issue 8, 2007, Pages 711-714

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GENERIC DRUG; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE NECROSIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL IRRITATION; HUMAN; HYPERCALCEMIA; JAW DISEASE; MOUTHWASH; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; HUMANS; NEOPLASMS; OSTEITIS DEFORMANS; OSTEOPOROSIS;

EID: 34347354461     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-006-0266-2     Document Type: Article

References (10)

1. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23: 508-16.
2. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. J Clin Endocrinol Metab 2000;85: 4118-24.
3. Bone HG, Hosking D, Devogelaer J, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350: 1189-99.
4. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Rev 2002;23: 517-23.
5. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344: 333-40.
6. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Mineral Res 2001;16: 1871-8.
7. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004;35: 224-30.
8. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353: 898-908.
9. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. Crit Rev Oncol/Hematol 2005;56: 365-78.
10. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006;355: 2278-81.